Search results for "TAXA"
showing 10 items of 268 documents
Towards Organization of Molecular Machines at Interfaces. Langmuir Films and Langmuir-Blodgett Multilayers of an Acid-Base Switchable Rotaxane
2006
In this context we investigated, for the first time, the organi-zation of a non-amphiphilic tricationic switchable rotaxaneand its dumbbell-shaped component into Langmuir films andLangmuir–Blodgett (LB) multilayers by using a cospreadingstrategy. The Langmuir films have been characterized by sur-face pressure–area (
Exentos de la fiscalidad del General en el Reino de Valencia. La reivindicación de inmunidad por el clero regular.
2020
Les relacions entre la Generalitat valenciana i el clergat regular experimentaren fortes tensions al segle XVII amb motiu de l’exempció fiscal dels eclesiàstics, especialment els mendicants. L’anàlisi d’aquests conflictes ens permet apropar-nos a la realitat efectiva d’un privilegi fiscal poc conegut en la seua incidència i derivacions.
Indicadors de mortalitat
2019
Conjunt de fulls de càlcul dissenyats amb Microsoft Excel (versió 2003) que permeten calcular, per a un sexe (homes, dones o total) i un any concret, els principals indicadors de mortalitat d’una zona geogràfica. També els models de mortalitat i d’anys potencials de vida perduts. Les dades necessàries són: •Defuncions per causa de mort i grup d’edat -Causa de mort Llista de grans grups de causes de mort Llista reduïda de 102 causes (INE-CCAA) Llista de 86 causes (Registre de mortalitat de la Comunitat Valenciana) Qualsevol altra exhaustiva i exclusiva llista de causes de mort -Grups d’edat Grups quinquennals d’edat: 0 a 4 anys, 5 a 9 anys, ..., 80 a 84 anys i 85 i més anys. El grup d’edat e…
Selectivity of cyclodextrins as a parameter to tune the formation of pseudorotaxanes and micelles supramolecular assemblies. A systematic SANS study
2011
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG geförderten) Allianz- bzw. Nationallizenz frei zugänglich. This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively. We studied the formation of polypseudorotaxanes formed with cyclodextrins (CDs) threading a copolymer chain that forms self-assembled structures in water. The size of the CD cavity was chosen such that it is block selective with respect to the formation of inclusion complexes and therefore in terms of altering the structure of the copolymer self-assemblies in a systematic fashio…
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in pati…
2015
Aim: Breast International Group (BIG) 2-98 is a randomised phase III trial that tested the effect of adding docetaxel, either in sequence to or in combination with anthracycline-based adjuvant chemotherapy, in women with node-positive breast cancer (BC). Here, we present the 10-year final trial safety and efficacy analyses. We also report an exploratory analysis on the predictive value of Ki67 for docetaxel efficacy, in the BIG 2-98 and using a pooled analysis of three other randomised trials. Patients and methods: 2887 patients were randomly assigned in a 2 x 2 trial design to one of four treatments. The primary objective was to evaluate the overall efficacy of docetaxel on disease free su…
Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph node…
2014
Abstract Aim Adjuvant chemotherapy has changed dramatically in the last decades. Anthracycline-/Taxane-based and dose-dense chemotherapy regimens improved survival in node positive breast cancer. This study tries to answer the following questions: (1)Are there differences in survival dependent on chemotherapy regimens in stratified by number of positive lymph nodes/grading (G)/hormone receptor-status (HR)/T-stage? (2)Is it possible to attribute these effects to chemotherapy by only investigating patients who received 100% guideline-conform surgery, radiotherapy and endocrine therapy? Methods This is a German multi-centre (17 participating hospitals all certified as breast cancer centres) re…
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised pros…
2008
Platinum/taxane combinations are widely used in patients with carcinoma of unknown primary (CUP), yielding response rates of 30% and median overall survival of 9-11 months in selected patients. Yet these combinations have not been subject to a randomised trial to overcome selection bias, a major problem in CUP. We randomised 92 patients to either paclitaxel/carboplatin (arm A) or the non-platinum non-taxane regimen gemcitabine/vinorelbine (arm B). The primary endpoint was rate of practicability as defined: application of >or=2 cycles of therapy (1) with a maximal delay of 1 week (2) and survival of >or=8 months (3). Practicability was shown in 52.4% (95% CI 36-68%) in arm A and in 42.2% (95…
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study…
2013
Abstract Background We evaluated the pathological complete response (pCR) rate after neoadjuvant epirubicin, (E) cyclophosphamide (C) and docetaxel containing chemotherapy with and without the addition of bevacizumab in patients with triple-negative breast cancer (TNBC). Patients and methods Patients with untreated cT1c-4d TNBC represented a stratified subset of the 1948 participants of the HER2-negative part of the GeparQuinto trial. Patients were randomized to receive four cycles EC (90/600 mg/m2; q3w) followed by four cycles docetaxel (100 mg/m2; q3w) each with or without bevacizumab (15 mg/kg; q3w) added to chemotherapy. Results TNBC patients were randomized to chemotherapy without (n =…
Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.
2013
The first-generation taxanes, conventional paclitaxel and docetaxel, are established treatment options for adjuvant and metastatic breast cancer (MBC). However, these agents have limitations, including primary/secondary resistance and harsh toxicities. The introduction of paclitaxel albumin represents a significant advance in taxane therapy as the first of a new generation of taxanes. This agent utilizes albumin pathways to achieve enhanced and targeted drug delivery to the tumour. The lack of solvent also means that it is well tolerated, despite the lack of premedications. Paclitaxel albumin is licensed in the United States and Europe as ≥2nd-line therapy in MBC (260mg/m(2) once every thre…
Efficacy and Safety of First-Line Bevacizumab (BEV) Combined with Paclitaxel (PAC) According to Age: Subpopulation Analysis of a Large, Multicenter, …
2009
Abstract Background: In three randomized phase III trials (E2100, AVADO, RIBBON-1), the combination of Bev with taxane-based therapy significantly improved PFS and response rate versus taxane alone in HER2-negative MBC. Subpopulation analysis of AVADO suggested that the magnitude of the benefit derived from Bev was similar in older and younger pts (≥65 vs <65 years). To gain further information on the safety and efficacy of first-line Bev–pac in older pts treated in the real-life setting, we conducted a subpopulation analysis of data from an ongoing multicenter non-interventional study initiated after the approval of Bev in Germany. Materials and methods: Pts who had received no prio…